» Articles » PMID: 21906387

Septic AKI in ICU Patients. Diagnosis, Pathophysiology, and Treatment Type, Dosing, and Timing: a Comprehensive Review of Recent and Future Developments

Overview
Specialty Critical Care
Date 2011 Sep 13
PMID 21906387
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Evidence is accumulating showing that septic acute kidney injury (AKI) is different from non-septic AKI. Specifically, a large body of research points to apoptotic processes underlying septic AKI. Unravelling the complex and intertwined apoptotic and immuno-inflammatory pathways at the cellular level will undoubtedly create new and exciting perspectives for the future development (e.g., caspase inhibition) or refinement (specific vasopressor use) of therapeutic strategies. Shock complicating sepsis may cause more AKI but also will render treatment of this condition in an hemodynamically unstable patient more difficult. Expert opinion, along with the aggregated results of two recent large randomized trials, favors continuous renal replacement therapy (CRRT) as preferential treatment for septic AKI (hemodynamically unstable). It is suggested that this approach might decrease the need for subsequent chronic dialysis. Large-scale introduction of citrate as an anticoagulant most likely will change CRRT management in intensive care units (ICU), because it not only significantly increases filter lifespan but also better preserves filter porosity. A possible role of citrate in reducing mortality and morbidity, mainly in surgical ICU patients, remains to be proven. Also, citrate administration in the predilution mode appears to be safe and exempt of relevant side effects, yet still requires rigorous monitoring. Current consensus exists about using a CRRT dose of 25 ml/kg/h in non-septic AKI. However, because patients should not be undertreated, this implies that doses as high as 30 to 35 ml/kg/h must be prescribed to account for eventual treatment interruptions. Awaiting results from large, ongoing trials, 35 ml/kg/h should remain the standard dose in septic AKI, particularly when shock is present. To date, exact timing of CRRT is not well defined. A widely accepted composite definition of timing is needed before an appropriate study challenging this major issue can be launched.

Citing Articles

Clinically Evident Cardiopulmonary Congestion Does Not Significantly Impact the Prognosis of Patients With Septic Acute Kidney Injury.

Mund C, Asmus K, Safi W, Ritter O, Petrus D, Patschan S J Clin Med Res. 2024; 16(6):302-309.

PMID: 39027814 PMC: 11254307. DOI: 10.14740/jocmr5190.


The Impact of Continuous Veno-Venous Hemodiafiltration on the Efficacy of Administration of Prophylactic Doses of Enoxaparin: A Prospective Observational Study.

Aszkielowicz A, Steckiewicz K, Okragly M, Wujtewicz M, Owczuk R Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631081 PMC: 10457944. DOI: 10.3390/ph16081166.


Survival status and predictors of mortality among patients admitted to surgical intensive care units of Addis Ababa governmental hospitals, Ethiopia: A multicenter retrospective cohort study.

Endeshaw A, Fekede M, Gesso A, Aligaz E, Aweke S Front Med (Lausanne). 2023; 9:1085932.

PMID: 36816723 PMC: 9932811. DOI: 10.3389/fmed.2022.1085932.


The attributable mortality of sepsis for acute kidney injury: a propensity-matched analysis based on multicenter prospective cohort study.

Jia H, Jiang Y, Zheng X, Li W, Wang M, Xi X Ren Fail. 2023; 45(1):2162415.

PMID: 36637012 PMC: 9848315. DOI: 10.1080/0886022X.2022.2162415.


The attributable mortality of new-onset acute kidney injury among critically ill patients: a propensity-matched analysis based on a multicentre prospective cohort study.

Jiang Y, Xi X, Jia H, Zheng X, Wang M, Li W Int Urol Nephrol. 2022; 54(8):1987-1994.

PMID: 34997454 PMC: 9262803. DOI: 10.1007/s11255-021-03087-z.


References
1.
Hui-Stickle S, Brewer E, Goldstein S . Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001. Am J Kidney Dis. 2005; 45(1):96-101. DOI: 10.1053/j.ajkd.2004.09.028. View

2.
Vincent J . We should abandon randomized controlled trials in the intensive care unit. Crit Care Med. 2010; 38(10 Suppl):S534-8. DOI: 10.1097/CCM.0b013e3181f208ac. View

3.
Fletcher J, Bergman K, Feucht E, Blostein P . Continuous renal replacement therapy for refractory intracranial hypertension. Neurocrit Care. 2009; 11(1):101-5. DOI: 10.1007/s12028-009-9197-9. View

4.
Rana A, Sathyanarayana P, Lieberthal W . Role of apoptosis of renal tubular cells in acute renal failure: therapeutic implications. Apoptosis. 2001; 6(1-2):83-102. DOI: 10.1023/a:1009680229931. View

5.
Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A . Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem. 2004; 38(1):1-8. DOI: 10.1016/j.clinbiochem.2004.09.025. View